Maybe if you read the whole paragraph, in context, it will be helpful. Ben was not offering original research. He was offering his summary of the Prins paper (reference 153)
Among the most promising results using lysate pulsed dendritic cell vaccines has come from the UCLA research program led by Dr. Liau. In the most detailed report of the results (153) 15 newly diagnosed GBM patients and 8 patients with recurrent tumors (average age =51), received the initial dendritic vaccine (followed by three booster vaccines in combination with either POLY ICLC or imiquimod (applied locally to the injection site). For all patients, median time to progression was 15.9 months. Median survival time for newly diagnosed patients was 35.9 months, and 2- and 3-year survival rates were 77% and 58%. For recurrent patients, mean survival from the time of initial enrollment in the trial was 17.9 months. Subsequent reports have come from press releases from Northwest Biotherapeutics, the biotech company sponsoring the DCVax trials. Survival at four years has been 33 %, and 27% have exceeded six years (154). Currently underway is a large multi-center phase III trial.
References
153. Prins, R. M., Soto, H., Konkankit, V., et al. Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clinical Cancer Research, 2011, 17(6)., 1603-15
Market Data 
Markets 
AI
